title: Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.
abstract: Although new agents are implemented to cancer therapy, we lack fundamental understandings of the mechanisms of chemoresistance, the main obstacle to cure in cancer. Here we review clinical evidence linking molecular defects to drug resistance across different tumour forms and discuss contemporary experimental evidence exploring these mechanisms. Although evidence, in general, is sparse and fragmentary, merging knowledge links drug resistance, and also sensitivity, to defects in functional pathways having a key role in cell growth arrest or death and DNA repair. As these pathways may act in concert, there is a need to explore multiple mechanisms in parallel. Taking advantage of massive parallel sequencing and other novel high-throughput technologies and base research on biological hypotheses, we now have the possibility to characterize functional defects related to these key pathways and to design a new generation of studies identifying the mechanisms controlling resistance to different treatment regimens in different tumour forms.
authors.affiliation: 1] Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway [2] Department of Oncology, Haukeland University Hospital, Bergen, Norway.
authors.forename: P E
authors.initials: PE
authors.lastname: Lønning
authors.forename: S
authors.initials: S
authors.lastname: Knappskog
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004260:DNA Repair / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents